TRIM62

Across TCGA pan-cancer cohorts, TRIM62 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRIM62 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TRIM62 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TRIM62 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where TRIM62 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.637	0.292	.043	4	view →
LSCC	OS	Median	III,IV	0.888	0.554	.045	1	view →
LUAD	DFS	Tertile	All	0.908	0.955	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TRIM62–PDAC (OS)

Open the PDAC breakdown →